# Sermorelin References: The GHRH(1-29) Literature Cited Here

> Sermorelin references: the full citation list behind this review of the GHRH(1-29) record — Thorner 1996, Corpas 1992, Wilton 1993, Baker 2012, and more, with DOIs and PubMed links.

Every study quoted across this reading desk, with authors, journal, year, and a resolvable DOI or PubMed link.

## How to read this list

The sermorelin references below are numbered to match the inline markers throughout the site. Each entry carries the full citation and a resolvable link — a DOI or a PubMed (PMID) URL — so any figure quoted in the digest can be traced to its source. Where a study used a stabilized GHRH analog (tesamorelin) rather than sermorelin itself, the text flags that distinction; the citation is listed here either way. This is the complete record behind the review; nothing in the body draws on a source absent from this list.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. NCT00257712. https://pubmed.ncbi.nlm.nih.gov/22869065/
[7] Lanes R, Carrillo E. Long-term therapy with a single daily subcutaneous dose of growth hormone releasing hormone (1-29) in prepubertal growth hormone deficient children. Venezuelan Collaborative Study Group. J Pediatr Endocrinol. 1994;7(4):303-8. https://pubmed.ncbi.nlm.nih.gov/7735367/
[8] Gelander L, Lindstedt G, Selstam G, et al. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion. Horm Res. 1989;31(5-6):213-20. https://pubmed.ncbi.nlm.nih.gov/2515143/
[9] Tauber MT, Pienkowski C, Pigeon P, et al. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Acta Paediatr Suppl. 1993;388:28-30; discussion 31. https://pubmed.ncbi.nlm.nih.gov/8329829/
[10] Neyzi O, et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl. 1993;388:16-21; discussion 22. https://pubmed.ncbi.nlm.nih.gov/8329826/
[11] Massoud AF, et al. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 1991;72(2):492-499. https://pubmed.ncbi.nlm.nih.gov/1671389/
[12] Lewinski A, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol (Lausanne). 2021;12:636403. https://pubmed.ncbi.nlm.nih.gov/33776931/
[13] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[14] Villar-Gouy KR, Salmon CEG, et al. Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiency. J Endocrinol Invest. 2024;47(11):2817-2827. https://pubmed.ncbi.nlm.nih.gov/38627331/
[15] Gahete MD, et al. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2025;26(1):1-18. https://pubmed.ncbi.nlm.nih.gov/39579280/

---

A reviewer's reading desk for the Sermorelin record — the GHRH(1-29) pediatric height-velocity, half-life, and adult GH/IGF-1 figures loaded into one window and read straight from the published literature; no clinic behind the screen and nothing here sourced, dispensed, or sold.